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Introduction
For patients with lung cancer preoperative evaluation of the mediastinal 
lymph nodes is important to estimate local operabiliy or/and to consider 
the necessity of neoadjuvant treatment. Cervical mediastinoscopy (CM) 
is generally accepted as a safe and highly accurate procedure in the 
staging of lung cancer. Nodes accessible to CM are the levels of supe-
rior (level 2R and 2L) and inferior (level 4R and 4L) paratracheal and 
subcarinal (level 7) nodal stations. Aditionally extended CM and left 
parasternal mediastinotomy allow the exploration of aortopulmonary 
window (level 5) and anterior mediastinal nodes (level 6). Until the be-
ginning of the nineties, repeat mediastinoscopy (RM) was considered to 
be contraindicated because of ﬁbrosis, due to prior exploration and the 
increased surgical risk to injure vital structures. Neoadjuvant clinical 
trials with induction chemotherapy or chemoradiation made necessary 
this agressive re-exploration of the upper mediastinum in order to select 
patients with a higher probability to undergo complete resection and 
reduce the number of explorative thoracotomies in patients with locally 
advanced lung cancer. These series included small number of patients, 
but demonstrated a technical feasibility and a high diagnostical accu-
racy. Further indications were reported in patients after insufﬁcient ﬁrst 
mediastinoscopy and in the assessment of recurrent or second primary 
lung neoplasms. 
The aim of this presentation is to represent the large experience of one 
institution with this method, specially the indications, the technical 
characteristics, the intra- and postoperative complications, at least the 
efﬁcacy of RM as a staging procedure in view of new methods like the 
positron emission tomography (FDG-PET and FDG-PET/CT) and the 
endobronchial (EBUS) or endoscopic (EUS) ultrasound guided ﬁne-
needle aspiration (FNA). 
Material and methods
From 1968 to 2004 279 patients (66 females and 213 males with a 
mean age of 58 years, range, 28 to 78years) with lung cancer under-
went a re-do-mediastinoscopy, 12 because of inadequate ﬁrst procedure 
(group A), 67 because of recurrent (group B) and 35 of second primary 
lung cancer (group C), ﬁnally 165 after induction chemo-/radiotherapy 
for IIIa and IIIb disease (group D). Before induction 116 patients 
had a N2 and 49 a N3-disease. Neoadjuvant treatment included 3 
courses chemotherapy (three cycles of split-dose cisplatin 60mg/m2 
days 1,7 and etoposide 150mg/m2 days 3,4,5) followed by concurrent 
chemoradiotherapy(one cycle cisplatin 50mg/m2 days 2,9 and etoposide 
100mg/m2 days 4,5,6 combined with 45 Gy hyperfractionated acceler-
ated radiotherapy to primary tumor and mediastinal nodes). Restaging 
was performed by means of CT scan of the chest and upper abdomen, 
CT of the brain, bone scan and bronchoscopy. Patients with radiologi-
cal evidence of tumor remission or stable disease and Karnowsky 
index of more than 70% underwent RM. The interval between ﬁrst and 
second procedure were in group A 17 days (range, 12 to 38), in group B 
14 months (5 to 29 months) in group C 27 months (19-124 months) and 
in group D 132 days (113-145). RM was performed with resection of 
the scar of the ﬁrst operation and preparation to the pretracheal fascia. 
Digital maneuver or/and sharp preparation followed with determina-
tion and removal of adhesions along the „mediastiniscopy route”. After 
inserting the mediastinoscope we tried to obtain biopsies from the same 
nodal stations as by the ﬁrst mediastinoscopy. Sometimes is technicaly 
easer to insert the mediastinoscope through the left side of the trachea, 
because the careful preservation of the recurrens nerve by the initial 
mediastinoscopy resulted to less nodal biopsies and less adhesions. All 
accessible lymph nodes were sampled and mapped according to the 
revised regional lymph node classiﬁcation for lung cancer by Moun-
tain. A RM was considered as complete if bilateral inferior paratracheal 
(level 4R and 4L) and subcarinal (level 7) nodal stations were reached.
Results
Non intra- or postoperative deaths was observed, the loss of blood dur-
ing the procedure amounted on an average of 26 ml (range 10 to 160 
ml) and was not different to the ﬁrst operation. Three patients devel-
oped postoperative a recurrens nerve palsy, two a wound infection and 
two a cardiac arrhytmia. Because of the presence of diffuse inseparable 
adhesions. RM was not possible in 5 and incomplete in 14 cases (1.8% 
and 5.2% respectively). RM proved a N2 or N3 disease in 3/12 cases 
of group A (25%), in 17/67 of group B (25.4%) and in 6/35 of group C 
(17.1%). In the group D 116 patients had N2 and 49 N3 disease before 
induction treatment. The most frequent histological type found was 
squamous cell carcinoma (59p.) followed by adenocarcinoma (55p.), 
large cell carcinoma (19p.), small cell carcinoma (28p.) and mixed type 
of lung cancer in 4 cases. During the 160 RM biopsies was taken by a 
total of 528 lymph node stations (mean, 3.3). 
Comment
46 years after its introduction by Carlens in 1959, CM continues to be 
an important step in evaluation of the mediastinal lymph node status 
and in selection of patients with lung cancer before surgery. RM were 
rare and the number of demonstrated cases very limited, so that any 
analysis of these data were doubtful and questioned. Furthermore RM 
considered to be as a difﬁcult and complex operation because of the 
presense of peritracheal adhesions particularly between the trachea and 
the innominate artery. Meersschaut et al. reported ﬁrst about a large 
series of 140 RM as a routine staging procedure without deaths due to 
the procedure and without complications necessitating surgical inter-
vention. RM has been performed for different indications: in patients 
with incomplete ﬁrst mediastinoscopy, assessment of recurrent tumors, 
assessment of second primary tumors and in patients after neoadjuvant 
chemotherapy. Mediastinoscopy has been also compared with other 
diagnostical examinations, particularly with imaging techniques as 
computed tomography and magnetic resonance. CT scan and MRI are 
unable to distinguish hyperplastic, antracotic, granulomatous nodes 
or ﬁbrotic tissue after induction treatment from malignant nodes. The 
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sensitivity and speciﬁcity of 69% and 71% of CT scan and 45% and 
65% of MRI respectively does not provide sufﬁcient informations for 
these patients. Modern techniques as positron emission tomography 
(FDG-PET or FDG-PET/CT) and endobronchial (EBUS) or endo-
scopic (EUS) ultrasound guided ﬁne-needle aspiration (FNA) have 
also been used for mediastinal staging. In a prospective study with 
202 patients found Gonzalez-Strawinski and al. that current FDG-PET 
technology alone does not appear to be sufﬁcient to warrant reliable 
treatment changes or the avoidance of mediastinoscopy in the evalu-
ation of patients with NSCLC. FDG-PET results have been shown to 
be difﬁcult to interpret after radiotherapy and the best time to repeat it 
still remains unproved. An inherent problem of the FDG contrast is that 
inﬂamed tissue will absorb it, so that granulomatous or inﬂammatory 
mediastinal disease or cases of obstructive malignant processes resulted 
to difﬁculty identifying mediastinal malignancy with FDG-PET. In our 
series we found that patients after induction chemoradiotherapy showed 
a strongly FDG accumulation due to inﬂammatory reaction of radiated 
mediastinal tissue, so that the number of false postive cases ranged by 
20%. Hellwig et al reported about the high negative predictive value in 
mediastinal restaging of FDG-PET so that only low values of lowstan-
dardized uptakes allows for omission of RM .
EBUS and EUS guided FNA are promising technique for staging of 
solid lesions and lymph nodes located adjacent to the trachea, the main 
bronchi and the esophagus but is not comparable to mediastinoscopy 
or RM . Selection of the patients for EUS or EBUS-FNA was based 
on computed tomographic scanning and with that only in patients with 
pathological radiological ﬁndings. Both techniques are used to assese 
the entire mediastinun or to stage predominantly only one nodal sta-
tion, but they are not used for the systematical standarized exploration 
of individual nodes as performed by mediastinoscopy. Moreover, the 
echogenic characteristics alone of a node might not be as reliable after 
radiation as they are before. In our experience representative material 
from scarred and ﬁbrotic lymph nodes after chemoradiotherapy is dif-
ﬁcult to be taken, the number of false positive results in the cytologic 
examination of FNA should be not underestimated. Particularly for 
local advanced disease and neoadjuvant treatment a histological tissue 
diagnosis must still be obtained, so that it is unlikely that the addition 
of transtracheal, transbronchial, and endoscopic ultrasonographically 
guided FNA will sufﬁciently rule out disease relative to the histologic 
results achieved from mediastinoscopy. EBUS and EUS are supple-
mentary diagnostical tools and may contribute to improve staging, 
especially in cases with metastasis in the hilar nodes or the mediastinal 
nodes which could not be reached by CM or RM.
Some investigators have focused on an early intensiﬁcation of preop-
erative downstaging by bimodality induction including chemotherapy 
as well as radiation therapy before surgery. In these patients the clinical 
classsiﬁcation especially the mediastinal staging after the induction 
treatment must yield the possible maximal accuraccy. Bueno et al 
and Voltolini et al pointed out in two separate reports that nodal stage 
after induction therapy for stage IIIA lung cancer determines patient 
survival. Downstaged patients to N0 status survived 59% at 3 years 
and 35.8% at 5 years respectively. However as have been proved the 
persistence of lymph node involvement after induction treatment has 
a discouraging prognosis with 3 years survival of 0% in the ﬁrst and 
5 years survival of 9% in the second study. This data support surgical 
resection only for downstaged patients and that a direct effort should be 
made to improve the accuracy of restaging before resection. Because 
of this, our oncological group considered to performe the RM in order 
to re-evaluate the mediastinum taken biopsies and verifying the nodal 
status in all patients entered into two complete phase II and one phase 
III trial and selecting patients for resection. Technical aspects of RM 
are well described in previous reports. The presence of peritracheal ad-
hesions makes the exploration more complex than by the initial medias-
tinoscopy. Analogous to other reports we did´t have a perioperative or 
postoperative mortality. A low rate of morbidity was observed (4.2 %) 
concient with reported results from other series. Furthermore additional 
operations due to intraoperative complications were not necessary. The 
incidence of recurrent nerve palsy was in accordance with the numbers 
after ﬁrst mediastinoscopy. 
We conclude that RM is a feasible and safe surgical procedure for 
restaging of patients with primary locally advanced, recurrent or second 
primary lung cancer. There are no mortality, the perioperative com-
plications rate are very low. In patients after induction treatment RM 
proved to be less sensitive than the ﬁrst procedure because of adhe-
sions and ﬁbrotic tissue. Because of the higher sensitivity, speciﬁcity 
and accuracy in compare to radiological investigations, FDG-PET and 
ultrasound guided FNA remains RM despite the technical complexity 
the criterion standard for mediastinal restaging in patients with local 
advanced lung cancer and induction treatment. 
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The Tumour, Node, Metastases (TNM) system for the classiﬁcation 
of malignant tumours was developed by Pierre Denoix in a series of 
papers between 1943 and 1952 (1;2). In 1953 it was accepted by the 
International Union Against Cancer (UICC) Committee on Tumour 
Nomenclature and Statistics. In 1968 it appeared in the 1st edition of 
their Classiﬁcation of Malignant Tumours. In 1973 the American Joint 
Committee on Cancer (AJCC) Task Force on Lung Cancer accepted the 
recommendations of Drs. Mountain, Carr and Anderson for a clini-
cal staging system of lung cancer (3). The following year the UICC 
accepted these proposals, unifying the 2 staging systems, in their 2nd 
edition of the TNM Classiﬁcation of Malignant Tumours.
The AJCC recommendations were based upon a database which con-
sisted of 1,712 cases of non-small cell lung cancer (NSCLC) diagnosed 
at least 4 years before the analysis of results. Nearly all of the descrip-
tors used today in staging lung cancer were established in that relatively 
small database, including the only size cut off for T descriptors (that of 
3 cms which distinguishes T1 from T2 tumours), the impact of speciﬁc 
areas of local invasion (visceral pleura, diaphragm, chest wall and the 
mediastinum and its contents), the proximal bronchoscopic extent of 
disease, pleural effusion and the extent of atelectasis or pneumonitis. 
In this version the highest “T” descriptor was 3, that for “N” was 2 and 
the highest stage was stage III.
Since that pioneering work there have been 4 more revisions. The size 
of the database on which these changes were made has increased, to 
5319 in the 5th revision (4), the review process has become progres-
sively more “International” and a few new descriptors have been added, 
resulting in the expansion of the “T” category to 4, the “N” category 
